Literature DB >> 2955039

The immune response and the eye. II. The nature of T suppressor cell induction in anterior chamber-associated immune deviation (ACAID).

T A Ferguson, J C Waldrep, H J Kaplan.   

Abstract

We studied the cellular basis for the induction of Ts cells in anterior chamber (AC)-associated immune deviation (ACAID) by using TNP-modified syngeneic spleen cells (TNP-Spl). We demonstrate that the cells responsible for the induction of TNP-ACAID are non adherent, IA- T cells. This is in contrast to the antigen-presenting cells which induce suppression after the i.v. injection of TNP-Spl which are IA+/I-J+ adherent cells. Furthermore, two T cells within the TNP-Spl population are required to initiate suppression in TNP-ACAID: one is Lyt-1+, and I-J+, the other is Lyt-1+ and reactive with a monoclonal antibody, 14-30, which specifically identifies Ts inducer cells. The antigen specificity of ACAID resides in the 14-30+ T cell, and not the I-J+ cell. Although both cells must be viable to induce suppression, neither they (nor their products) must be in direct contact within the eye; one population may be in the right AC, the other in the left. Our results suggest that it is Ts inducer cells placed into the AC of the eye which initiate TNP-ACAID, and that these cells exit (or secrete Ts factors which exit) the eye to induce Ts effector cells in the spleen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955039

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Immunoregulatory properties of bone marrow-derived cells in the iris and ciliary body.

Authors:  J S Williamson; D Bradley; J W Streilein
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

2.  Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations.

Authors:  G A Wilbanks; J W Streilein
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

Review 3.  Cell death and the immune response: a lesson from the privileged.

Authors:  T A Ferguson; T S Griffith
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

4.  Ability of intracamerally inoculated B- and T-cell enriched allogeneic lymphocytes to enhance corneal allograft survival.

Authors:  S C She; E J Moticka
Journal:  Int Ophthalmol       Date:  1993-02       Impact factor: 2.031

5.  Requirement for splenic CD4+ T cells in the immune privilege of the anterior chamber of the eye.

Authors:  M Takahashi; N Ishimaru; K Yanagi; K Saegusa; N Haneji; H Shiota; Y Hayashi
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

6.  Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cells.

Authors:  Thomas S Griffith; Erik L Brincks; Prajwal Gurung; Tamara A Kucaba; Thomas A Ferguson
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

7.  Distinctive humoral immune responses following anterior chamber and intravenous administration of soluble antigen. Evidence for active suppression of IgG2-secreting B lymphocytes.

Authors:  G A Wilbanks; J W Streilein
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

8.  Functional studies of major histocompatibility class II-positive dendritic cells and resident tissue macrophages isolated from the rat iris.

Authors:  R J Steptoe; P G Holt; P G McMenamin
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

9.  The regulation by light of retinal necrosis and the immune response following anterior chamber inoculation of herpes simplex virus type-1.

Authors:  M Kahn; H J Kaplan; T A Ferguson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis.

Authors:  Y Gao; J M Herndon; H Zhang; T S Griffith; T A Ferguson
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.